bile duct cancer
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
Juniper Biologics to Sell Helsinn's Truseltiq in Certain Asia-Pacific, Africa, Middle East Markets
The deal gives Juniper exclusive rights to develop and commercialize Helsinn's bile duct cancer drug in 40 new countries.
Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer
The firm is evaluating its TCR-T cell therapy, engineered with the Sleeping Beauty transposon/transposase system, for solid tumors with certain hotspot mutations.Â
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor
With KIN-3248, Kinnate aims to overcome acquired resistance to FGFR inhibitors in patients with bile duct cancer and urothelial cancer bearing alterations in FGFR2 and FGFR3.Â